173 related articles for article (PubMed ID: 15277263)
1. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.
Nabhan C; Rundhaugen L; Jatoi M; Riley MB; Boehlke L; Peterson LC; Tallman MS
Ann Oncol; 2004 Aug; 15(8):1231-6. PubMed ID: 15277263
[TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
McKoy JM; Angelotta C; Bennett CL; Tallman MS; Wadleigh M; Evens AM; Kuzel TM; Trifilio SM; Raisch DW; Kell J; DeAngelo DJ; Giles FJ
Leuk Res; 2007 May; 31(5):599-604. PubMed ID: 16959316
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
[TBL] [Abstract][Full Text] [Related]
5. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry.
Magwood-Golston JS; Kessler S; Bennett CL
Leuk Res; 2016 May; 44():61-4. PubMed ID: 27030962
[TBL] [Abstract][Full Text] [Related]
7. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
8. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation.
Chevallier P; Prebet T; Turlure P; Hunault M; Vigouroux S; Harousseau JL; Blaise D; Ifrah N; Milpied N; Mohty M
Bone Marrow Transplant; 2010 Jan; 45(1):165-70. PubMed ID: 19584826
[TBL] [Abstract][Full Text] [Related]
9. Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis.
O'Boyle KP; Murigeppa A; Jain D; Dauber L; Dutcher JP; Wiernik PH
Med Oncol; 2003; 20(4):379-84. PubMed ID: 14716035
[TBL] [Abstract][Full Text] [Related]
10. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Wadleigh M; Richardson PG; Zahrieh D; Lee SJ; Cutler C; Ho V; Alyea EP; Antin JH; Stone RM; Soiffer RJ; DeAngelo DJ
Blood; 2003 Sep; 102(5):1578-82. PubMed ID: 12738663
[TBL] [Abstract][Full Text] [Related]
11. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
Amadori S; Suciu S; Willemze R; Mandelli F; Selleslag D; Stauder R; Ho A; Denzlinger C; Leone G; Fabris P; Muus P; Vignetti M; Hagemeijer A; Beeldens F; Anak O; De Witte T; ;
Haematologica; 2004 Aug; 89(8):950-6. PubMed ID: 15339678
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
13. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
Leopold LH; Berger MS; Feingold J
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
[TBL] [Abstract][Full Text] [Related]
14. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
Rajvanshi P; Shulman HM; Sievers EL; McDonald GB
Blood; 2002 Apr; 99(7):2310-4. PubMed ID: 11895761
[TBL] [Abstract][Full Text] [Related]
15. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
[TBL] [Abstract][Full Text] [Related]
16. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
17. Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice.
Tallman MS; McDonald GB; DeLeve LD; Baer MR; Cook MN; Graepel GJ; Kollmer C
Int J Hematol; 2013 Apr; 97(4):456-64. PubMed ID: 23460018
[TBL] [Abstract][Full Text] [Related]
18. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
20. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
